Symple Surgical Awarded SBIR Phase I Grant for Novel Radiometry‐Guided Ablation Catheter to Reliably Treat Barrett's Esophagus
February 01, 2022 09:00 ET | Symple Surgical
FLAGSTAFF, Ariz., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Symple Surgical Inc. (SSI) announced today that it has received a Small Business Innovation Research (SBIR) Phase I grant award totaling...
National Cancer Institute (NCI) Extends Long-Standing Partnership with Inspirata
September 29, 2020 10:26 ET | Inspirata, Inc.
Tampa, Florida, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Inspirata announced today the renewal of its long-standing partnership with the National Cancer Institute (NCI). Building on almost two decades of...
LIXTE.jpg
Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors
April 30, 2020 10:30 ET | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, April 30, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that investigators at the National Cancer Institute (NCI) and National Institute of...
LIXTE.jpg
First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology’s LB-100 to Enter Recurrent Malignant Brain Tumors
December 04, 2019 09:35 ET | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the National Cancer Institute (NCI) has enrolled the first two patients of a...
LIXTE.jpg
First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology’s LB-100 in Low or Intermediate-1 Risk Myelodysplastic Syndrome
July 18, 2019 09:35 ET | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, July 18, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the first patient has been enrolled in its Phase 1b/2 study of the safety and...
LIXTE.jpg
Lixte Biotechnology's LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors
May 15, 2019 09:35 ET | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, May 15, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced the opening of a pharmacologic study of the ability of its lead clinical compound,...
Karmanos Cancer Institute presents 25th Annual Partners Night Friday, Sept. 21, at historic Michigan Building Theatre
August 23, 2018 07:05 ET | Barbara Ann Karmanos Cancer Institute
Honoring Jack D. Sobel, M.D.; Celebrating Partners silver anniversary of supporting Karmanos’ cutting-edge cancer research DETROIT, Aug. 23, 2018 (GLOBE NEWSWIRE) -- On Friday, Sept. 21, the...
Karmanos Cancer Institute-_NEW logo.jpg
Karmanos Cancer Institute hosts inaugural Prostate Cancer Awareness Game at Jimmy John’s Field, August 17
July 25, 2018 07:05 ET | Barbara Ann Karmanos Cancer Institute
DETROIT, July 25, 2018 (GLOBE NEWSWIRE) -- The Barbara Ann Karmanos Cancer Institute, in partnership with McLaren Macomb Foundation, joins the United Shore Baseball League for the inaugural Karmanos...
Karmanos Expands Cancer Network with Newest Location at McLaren Oakland
July 23, 2018 10:00 ET | Barbara Ann Karmanos Cancer Institute
PONTIAC, Mich., July 23, 2018 (GLOBE NEWSWIRE) -- The Barbara Ann Karmanos Cancer Institute and McLaren Oakland announced today it will open its 15th treatment location in Michigan at McLaren...
Karmanos Cancer Institute to begin renovations to expand services in Farmington Hills
May 18, 2018 08:10 ET | Barbara Ann Karmanos Cancer Institute
DETROIT, May 18, 2018 (GLOBE NEWSWIRE) -- The Barbara Ann Karmanos Cancer Institute announced today it will expand its Lawrence and Idell Weisberg Cancer Treatment Center in Farmington Hills into a...